Links from this page to related variants, conditions, drugs and topics are not included for automated readers. Those connections are the Gene Knowledge Graph and are licensed as data: https://www.mygenelog.com/license

Standard

Lactosylceramides (FA24:1) (Model 2)

ABCA7 · rs4147922

Strength of the evidence

3 / 4

Its strongest genetic-study result is p = 10−51, with 6 associations in the GWAS Catalog.

How this is scored

4: ClinVar disease-causing, reviewed by an expert panel or a guideline (3–4 stars). 3: ClinVar, several labs agreeing (2 stars), or a genetic study at p ≤ 10−50. 2: ClinVar from one lab (1 star), or p ≤ 10−20. 1: ClinVar submitted without criteria (0 stars), or genome-wide significance (p ≤ 5×10−8). The higher of the two counts. It says how solid the evidence is, not whether it matters for a particular person.

What the study found

Who was studied 7,126 European ancestry individuals.

The effect Each copy of the T allele shifted the measure 0.285 lower; p = 3 × 10−51.

Where it sits Chromosome 19, band 19p13.3 — in an intron of ABCA7.

How common each version is

CT
Korean KRGDB
C 46.2% · T 53.8%
Korean Korea4K
C 46.6% · T 53.4%
Korean Korea1K
C 46.4% · T 53.6%
Japanese ToMMo
C 43.0% · T 57.0%
World gnomAD
C 69.5% · T 30.5%
World 1000 Genomes
C 60.9% · T 39.1%
World TOPMed
C 69.5% · T 30.5%

By ancestry gnomAD

East Asian
C 44.9% · T 55.1%
European (non-Finnish)
C 73.7% · T 26.3%
African / African American
C 62.2% · T 37.8%
South Asian
C 60.5% · T 39.6%
Admixed American (Latino)
C 77.1% · T 22.9%
Middle Eastern
C 79.2% · T 20.8%
Finnish
C 75.0% · T 25.0%
Ashkenazi Jewish
C 72.0% · T 28.0%

The share of all copies of this position that are each version. Source: the population studies published in dbSNP (US NCBI); each row names its study. The ancestry rows are gnomAD's own groups (via Ensembl), as the survey defines them, not races.

What each result means

C/C No copy of the version the research linked to Lactosylceramides (FA24:1) (Model 2). This is the starting point the study compared everyone against.
C/T One copy of the version the research linked to Lactosylceramides (FA24:1) (Model 2). That is a smaller link than two copies.
T/T Two copies of the version the research linked to Lactosylceramides (FA24:1) (Model 2). That is the strongest link of the three results. A link in a study is not a diagnosis.
Source

Quoting this page

Licensed CC BY-NC 4.0: free to read, share and adapt for non-commercial use, naming MyGeneLog™ and linking the exact page. Commercial use, including training or serving a commercial AI system, needs a licence — https://www.mygenelog.com/license

Lactosylceramides (FA24:1) (Model 2) (rs4147922). MyGeneLog™. https://www.mygenelog.com/variants/rs4147922

← See all variants